Urinary Retention Management

Initial Assessment and Management

• Patients with suspected urinary retention should undergo assessment through bladder scanning or straight catheterization to confirm the diagnosis and quantify residual volume, as recommended by the American Heart Association and other guideline societies 1, 2
• Immediate bladder decompression via urethral catheterization should be performed for relief of acute urinary retention, according to the American College of Cardiology 2
• Silver alloy-coated urinary catheters should be considered to reduce urinary tract infection risk, as suggested by the American Urological Association 3

Diagnostic Evaluation

• Urethrocystoscopy or retrograde urethrogram (RUG) should be performed to diagnose urethral stricture if suspected as the cause, as recommended by the American Urological Association 4
• For suspected posterior urethral injury, both retrograde urethrography and voiding cystourethrogram (VCUG) should be obtained to delineate the stricture length and location, according to the World Health Organization 5
• In patients with neurological conditions, urodynamic studies may be necessary to assess detrusor function, as suggested by the American Heart Association 1
• Evaluate for constipation as a potential cause of urinary retention, particularly in elderly patients, as recommended by the American Geriatrics Society 3

Specific Management Based on Etiology

• Administer an alpha blocker (e.g., tamsulosin or alfuzosin) prior to attempting catheter removal to improve chances of successful voiding trial, as recommended by the American Urological Association 6, 2
• Surgery is recommended for patients with refractory retention who have failed at least one attempt at catheter removal, according to the American Urological Association 6
• Intermittent catheterization is generally recommended for initial management rather than indwelling catheters, as suggested by the American Heart Association 1
• Treat underlying constipation with osmotic laxatives (polyethylene glycol, lactulose) or stimulant laxatives (bisacodyl, senna), as recommended by the American Gastroenterological Association 3

Follow-Up and Monitoring

• Patients who successfully void after catheter removal should be informed that they remain at increased risk for recurrent urinary retention, as recommended by the American College of Cardiology 2
• For patients with chronic retention requiring long-term catheterization, regular follow-up to assess for complications such as UTI, bladder stones, and renal function deterioration is essential, according to the British Medical Journal 7
• Indwelling catheters should be removed as soon as the patient is medically stable to reduce infection risk, as recommended by the American Heart Association and the American College of Cardiology 1, 2

Management of Urinary Retention

Initial Assessment and Management

• The American College of Cardiology is not relevant here, however, the use of silver alloy-coated urinary catheters can reduce urinary tract infection risk, and removal of the catheter as soon as possible, ideally within 48 hours, can minimize urinary tract infection risk 8

Specific Management Based on Etiology

For Urethral Stricture:

• The American Urological Association recommends urethral endoscopic management, such as urethral dilation or direct visual internal urethrotomy, or immediate suprapubic cystostomy for urgent management of urethral stricture, and for short bulbar urethral strictures, options include dilation, direct visual internal urethrotomy, or urethroplasty 9
• Consider self-catheterization after direct visual internal urethrotomy to maintain temporary urethral patency in patients who are not candidates for urethroplasty, as recommended by urology guidelines 9

Follow-Up and Monitoring

• Implement an individualized bladder-training program for patients with persistent urinary incontinence, and use prompted voiding techniques for patients with urinary incontinence, as recommended by stroke guidelines 8

Special Considerations

• For patients dependent on an indwelling urethral catheter or intermittent self-dilation, consider suprapubic cystostomy prior to definitive urethroplasty, as recommended by the Journal of Urology 9

Management Guidelines for Urinary Retention

Initial Assessment and Management

• Remove indwelling catheters as soon as medically possible, ideally within 24-48 hours, to minimize infection risk 10

Management Based on Etiology

For BPH-Related Retention:

• Surgical intervention should be considered for patients with refractory retention who have failed at least one attempt at catheter removal 11

For Special Considerations

• For patients with infected or obstructing urinary stones, immediate decompression is warranted 12
• In patients with post-stroke urinary retention, remove Foley catheters within 24 hours after admission when possible 13
• For high-risk patients who cannot undergo other treatments, prostatic stents may be considered, though they are associated with significant complications including encrustation, infection, and chronic pain 11

Management of Urinary Retention

Surgical Management Options

• The American Urological Association recommends transurethral resection of the prostate (TURP) as the benchmark for surgical therapies for BPH-related retention, with the selection of energy source and instrumentation based upon the surgeon's experience, patient's individual prostatic anatomy, and medical comorbidities 14, 15
• For high-risk patients who cannot undergo other treatments, prostatic stents may be considered, though they are associated with significant complications including encrustation, infection, and chronic pain 14

Management of Urinary Retention in BPH Patients

Initial Management

• The American Urological Association recommends administering a non-titratable alpha blocker (tamsulosin or alfuzosin) prior to attempted catheter removal to improve chances of successful voiding trial in patients with BPH, with a consideration for patients with prior history of alpha-blocker side effects or unstable medical comorbidities (e.g., orthostatic hypotension, cerebral vascular disease) 16

Trial Without Catheter

• A voiding trial is more likely to be successful if the underlying retention was precipitated by temporary factors (e.g., anesthesia or alpha-adrenergic sympathomimetic cold medications) in patients with BPH 16
• If the voiding trial fails, surgical intervention is recommended for patients with BPH 16

Surgical Management

• Surgery is recommended for patients with refractory retention who have failed at least one attempt at catheter removal, with transurethral resection of the prostate (TURP) remaining the gold standard surgical treatment for BPH-related urinary retention 16, 17, 18
• For patients who are not surgical candidates, treatment with intermittent catheterization, an indwelling catheter, or stent is recommended 16

Alternative Management Options

• Combination therapy with alpha blockers and 5-alpha reductase inhibitors may be more effective than monotherapy for preventing future episodes of retention in men with large prostates (>30cc) 19

Important Caveats

• Avoid delaying surgical intervention in patients with refractory retention, as this can lead to bladder decompensation and chronic retention 16, 17
• Surgery is also recommended for patients who have renal insufficiency, recurrent UTIs, recurrent gross hematuria, or bladder stones due to BPH and refractory to other therapies 16, 20

Management of Acute Urinary Retention

Initial Assessment and Special Considerations

• If blood is present at the urethral meatus after pelvic trauma, perform retrograde urethrography before attempting catheterization to rule out urethral injury, as recommended by the American Urological Association 21
• Avoid blind catheter passage prior to retrograde urethrogram in cases of suspected urethral injury, as it may exacerbate the injury 21
• If urethral injury is confirmed, suprapubic tube placement may be necessary for urinary drainage, according to the American Urological Association guidelines 21
• Transurethral resection of the prostate (TURP) remains the benchmark surgical treatment for BPH-related urinary retention, with a success rate of 60% vs 39% for placebo with alfuzosin, and 47% vs 29% for placebo with tamsulosin, as stated by the European Association of Urology 22
• For patients with stroke who have urinary retention, remove indwelling catheters as soon as the patient is medically and neurologically stable, as recommended by the American Heart Association 23
• Prolonged use of indwelling catheters increases the risk of urinary tract infections, and therefore should be avoided, according to the Centers for Disease Control and Prevention 23
• Prostatic stents should only be considered in high-risk patients who cannot undergo other treatments, as they are associated with significant complications including encrustation, infection, and chronic pain, as warned by the European Association of Urology 22

First-Line Treatment for Acute Urinary Retention

Immediate Management and Pharmacologic Therapy

• The American Urological Association recommends immediate bladder decompression via urethral catheterization followed by initiation of an oral alpha blocker, such as tamsulosin 0.4 mg or alfuzosin 10 mg once daily, as the first-line treatment for acute urinary retention in a 96-year-old man 24, 25
• Alpha blockers, such as tamsulosin and alfuzosin, improve trial without catheter (TWOC) success rates significantly, with alfuzosin achieving 60% success versus 39% with placebo, and tamsulosin achieving 47% versus 29% with placebo 25

Considerations for Elderly Patients

• Exercise caution with alpha blockers in elderly patients with orthostatic hypotension, cerebrovascular disease, or history of falls, as these medications can cause dizziness and postural hypotension 26, 24
• Tamsulosin may have a lower probability of orthostatic hypotension compared to other alpha blockers, making it potentially preferable in this age group 26

Trial Without Catheter (TWOC) and Post-TWOC Management

• Administer alpha blocker therapy for at least 3 days before attempting catheter removal 24, 25
• Counsel the patient that he remains at increased risk for recurrent urinary retention even after successful catheter removal 24, 25

Additional Evaluation and Common Pitfalls to Avoid

• Avoid using doxazosin or terazosin as first-line agents in acute retention, as these require titration and doxazosin has been associated with increased congestive heart failure in men with cardiac risk factors 26, 27
• Do not assume alpha blocker therapy alone will manage concomitant hypertension in this elderly patient; hypertension may require separate management 26

Treatment of Acute Urinary Retention

Pharmacologic Therapy

• The American Urological Association recommends immediate bladder decompression via urethral catheterization followed by oral alpha blocker therapy, with the alpha blocker started at the time of catheter insertion and continued for at least 3 days before attempting catheter removal 28
• Alfuzosin achieves 60% success versus 39% with placebo in trial without catheter (TWOC) success rates 28
• Tamsulosin achieves 47% success versus 29% with placebo in TWOC success rates 28
• Prescribe a non-titratable alpha blocker (tamsulosin 0.4 mg or alfuzosin 10 mg once daily) prior to voiding trial 28, 29
• Administer alpha blocker therapy for at least 3 days before attempting catheter removal 28

Management Based on Etiology

BPH-Related Retention

• Surgery is recommended for patients with refractory retention who have failed at least one attempt at catheter removal 28
• Combination therapy with alpha blockers and 5-alpha reductase inhibitors reduces the risk of progression by 67%, acute urinary retention by 79%, and need for surgery by 67% compared to placebo 30
• Finasteride reduces acute urinary retention risk by 57% and surgery risk by 55% 30
• For patients with prostatic enlargement, 5-alpha reductase inhibitors (finasteride or dutasteride) should be used for symptom improvement 29, 30

Management of Urinary Retention

Long-Term Management and Follow-Up

• The American Urological Association recommends that chronic indwelling urethral or suprapubic catheters should only be recommended when therapies are contraindicated, ineffective, or no longer desired by the patient, with suprapubic tubes preferred over urethral catheters due to reduced likelihood of urethral damage 31

Management of Acute Urinary Retention

Antibiotic Use

• The European Urology guidelines state that urinary retention alone does not warrant antibiotics without confirmed infection, and antibiotics should only be prescribed if systemic signs of infection are present or after culture confirms infection 32, 33, 34
• Culture results guide antibiotic decisions only if infection is confirmed, and treatment with appropriate antibiotics is recommended if culture shows significant bacteriuria with systemic symptoms 32, 33
• For catheter-associated UTIs, the same antimicrobial principles as other UTIs in elderly patients should be used, with fosfomycin, nitrofurantoin, fluoroquinolones, or cotrimoxazole being appropriate choices 32, 33

Management of Male Urinary Retention

Catheterization Frequency and Technique

• The American Urological Association recommends performing catheterization 4-6 times daily at regular intervals (approximately every 4-6 hours) to maintain bladder volumes below 400-500 mL and prevent bladder overdistension 35
• For chronic intermittent catheterization, hydrophilic or low-friction catheters show benefit in reducing complications 35
• Nighttime catheterization may be necessary depending on fluid intake patterns and bladder capacity 35
• If volumes are consistently low (<200 mL), frequency may be reduced, but maintain minimum of 4 catheterizations per day 35

Etiology-Specific Management

• For patients with neurogenic bladder, clean intermittent self-catheterization is the preferred long-term management strategy 36
• Urethroplasty may be offered as a treatment option for urethral stricture causing difficulty with intermittent self-catheterization 37, 38

Critical Pitfalls to Avoid

• Repeated intermittent catheterization for pelvic fracture urethral injury should be avoided, as this increases patient morbidity and delays definitive reconstruction 37, 38
• Indwelling catheters should only be used when intermittent catheterization is contraindicated, ineffective, or refused by the patient, and removed as soon as medically possible (ideally within 24-48 hours) to minimize infection risk 39
• Catheter-associated urinary tract infections account for nearly 40% of all nosocomial infections 39

Immediate Management of Acute Urinary Retention in Males

Initial Bladder Decompression

• The American Urological Association recommends placing a suprapubic catheter for drainage if urethral catheterization fails or urethral injury is confirmed 40

Pharmacologic Therapy

• The American Urological Association recommends starting an oral alpha blocker, such as tamsulosin 0.4 mg or alfuzosin 10 mg once daily, at the time of catheter insertion, and continuing for at least 3 days, with a success rate of 60% for alfuzosin and 47% for tamsulosin 41
• Alpha blockers significantly improve trial without catheter (TWOC) success rates, with alfuzosin achieving 60% success versus 39% with placebo, and tamsulosin achieving 47% versus 29% with placebo 41

Trial Without Catheter (TWOC)

• The American Urological Association recommends keeping the catheter in place for at least 3 days of alpha blocker therapy before attempting removal, as there is no evidence that catheterization longer than 72 hours improves outcomes, and prolonged catheterization increases infection risk 41, 40

Etiology-Specific Considerations

• For urgent management of urethral stricture, options include urethral dilation, direct visual internal urethrotomy, or immediate suprapubic cystostomy 40

Alpha Blocker Therapy Duration and Management

Long-Term Management Considerations

• For patients with underlying benign prostatic hyperplasia (BPH) or persistent lower urinary tract symptoms, the American Urological Association suggests considering indefinite alpha blocker therapy as these medications are appropriate long-term treatment options 42
• Tamsulosin may have a lower probability of orthostatic hypotension compared to doxazosin or terazosin, making it preferable in high-risk patients, according to the American Urological Association 42
• The European Association of Urology recommends that patients with persistently elevated post-void residual (PVR) volumes (>150 mL) may require continued alpha blocker therapy 43

Management of Acute Urinary Retention

Diagnostic Evaluation

• The American College of Radiology recommends assessing renal function with serum creatinine and BUN, as urinary retention can cause post-renal acute kidney injury, and renal ultrasound has >90% sensitivity for detecting hydronephrosis 44, 45

Imaging Studies

• Renal ultrasound is recommended if creatinine is elevated to assess for hydronephrosis, with a sensitivity of >90% for detecting hydronephrosis 44, 45

Management of Acute Functional Urinary Retention in Women

First‑Line Therapeutic Approach

• Intermittent catheterization is recommended as the primary treatment for acute functional (non‑obstructive) urinary retention in women, superseding pharmacologic options. The Journal of Urology (2021) supports this recommendation based on clinical evidence. 46
• Clean intermittent catheterization (CIC) should be performed 4–6 times daily at regular intervals, keeping bladder volumes below 400–500 mL. This schedule is derived from the same 2021 guideline evidence. 46

Catheter Choice and Complication Risk

• Indwelling (continuous) catheters are associated with higher rates of urinary‑tract infection, urethral trauma, and bladder stone formation compared with intermittent catheterization. The Journal of Urology (2021) cites comparative outcome data. 46

Management of Neurogenic Bladder Atony

• Long‑term intermittent catheterization remains the cornerstone of care for neurogenic bladder atony in women. This recommendation is drawn from the 2021 evidence base. 46

Use of Antimuscarinic Medications

• Antimuscarinic agents (e.g., oxybutynin, solifenacin, mirabegron) must be avoided or used only with extreme caution in women with urinary retention. The American Urological Association (AUA) and Society of Urodynamics, Female Urology (SUFU) guidelines (2012) explicitly advise against routine use. 47
• The AUA/SUFU guidelines state that antimuscarinics should not be prescribed to patients with a history of urinary retention unless under strict cautionary conditions. This is a guideline‑level recommendation. 47
• A pre‑treatment post‑void residual (PVR) measurement is required before initiating any antimuscarinic therapy in at‑risk patients. The 2012 AUA/SUFU guidance specifies this safety step. 47
• Combining bethanechol with antimuscarinic drugs is contraindicated because the opposing pharmacologic actions can exacerbate urinary retention. The AUA/SUFU (2012) highlights this interaction risk. 47

Optimal Timing and Management of Voiding Trial after Foley Catheter for BPH‑Related Retention

Timing of Catheter Removal

• Attempt catheter removal after a minimum of 3 days (and no later than 7–8 days) of tamsulosin therapy; 3 days is the most frequently supported interval in both guidelines and clinical trials. 48
• Alpha‑blockers need 2–3 days to reach therapeutic tissue concentrations and produce maximal smooth‑muscle relaxation of the prostate and bladder neck. 49

Predictors of Voiding‑Trial Success

• Higher success rates are observed when the acute retention episode is precipitated by temporary factors (e.g., anesthesia, decongestant use, postoperative state) rather than by chronic progressive obstruction. 48

Pharmacologic Contra‑indications

• Tamsulosin should be avoided in patients with orthostatic hypotension, cerebrovascular disease, or a history of syncope, as these conditions constitute relative contraindications. 49

Indications for Early Surgical Referral

• If a single voiding trial fails, referral for definitive surgical intervention is recommended, because one failed trial defines refractory retention. 48
• Surgery should not be delayed in patients who have renal insufficiency, recurrent urinary‑tract infections, gross hematuria, or bladder stones attributable to BPH. 49

Poor Prognostic Factors for Recurrent Retention

• Chronic progressive lower‑urinary‑tract symptoms (as opposed to an acute precipitating event) predict a higher likelihood of recurrent retention. 48

All statements are supported by evidence from the cited studies in The Journal of Urology* (2003).

Urethral Stricture Evaluation and Management in Acute Urinary Retention with Normal Prostate Size

Diagnostic Approach

• Urethral stricture should be considered a primary cause of acute urinary retention when prostate size is normal, and diagnosis requires imaging with a retrograde urethrogram. The recommendation is based on evidence from The Journal of Urology (2023) 50; strength of evidence not specified.

Therapeutic Options

• When a urethral stricture is identified as the etiology of retention, treatment may include urethral dilation, direct visual internal urethrotomy, or urethroplasty, selected according to the stricture’s length, location, and severity. This therapeutic algorithm is supported by The Journal of Urology (2023) 50; strength of evidence not specified.

Emergency Department Management of Chronic Urinary Retention

Initial Management of Complicated Chronic Retention

• In patients with habitual urinary retention who present to the emergency department with acute complications (e.g., pain, inability to void, infection, or renal impairment), immediate bladder decompression with urethral catheterization provides rapid symptomatic relief and prevents further bladder injury. Evidence: observational study in Annals of Emergency Medicine (2006). 51

Catheter‑Related Care

• After decompression, indwelling urinary catheters should be removed or exchanged within 24–48 hours to limit the risk of catheter‑associated urinary tract infection, which rises markedly after two days of continuous catheterization. Evidence: cohort analysis in International Journal of Stroke (2018). 52

Imaging Recommendations

• For uncomplicated chronic urinary retention, extensive emergency‑department imaging (CT, MRI, or cystoscopy) is not indicated, as these modalities do not alter immediate management and expose patients to unnecessary radiation and cost. Evidence: imaging guideline review in Journal of the American College of Radiology (2020). 53
• The same guideline emphasizes that ultrasound may be reserved for cases with suspected hydronephrosis or renal dysfunction, rather than routine use in all chronic retention presentations. Evidence: imaging guideline review in Journal of the American College of Radiology (2020). 54

Emergency Department Management of Catheterized Patients with Recurrent Urinary Retention

Indications for Immediate ED Evaluation

• Febrile catheterized patients require urgent assessment, including upper‑tract imaging (renal ultrasound or CT) when they do not improve with antibiotics or belong to a moderate‑to‑high risk group lacking up‑to‑date imaging. (American Urological Association recommendation) 55, 56
• Suspected catheter‑associated urinary tract infection (UTI) mandates urinalysis and urine culture after the catheter is exchanged and urine is allowed to accumulate; specimens must not be taken from extension tubing or collection bags. (American Urological Association recommendation) 55

Infection Prevention and Catheter Management

• Indwelling catheters should be removed as early as feasible (ideally within 24–48 h) because catheter‑associated UTI risk rises by roughly 5 % each day of continued use. (American College of Emergency Physicians) 57
• Routine daily antibiotic prophylaxis is not advised for patients with indwelling catheters; it fails to prevent UTIs and fosters antimicrobial resistance. (American Urological Association) 55
• Urine cultures are indicated only when patients exhibit UTI signs (fever, suprapubic pain, altered mental status, hemodynamic instability); they are unnecessary for asymptomatic bacteriuria. (American Urological Association) 55
• Before obtaining a culture, the catheter must be exchanged to avoid sampling biofilm‑laden urine from the old device. (American Urological Association) 55, 56
• Asymptomatic bacteriuria should not be treated unless the patient is pregnant or scheduled for a urologic procedure that will disrupt the urothelium. (American Urological Association) 55

Outpatient Evaluation Recommendations

• Patients with recurrent UTIs despite an indwelling catheter should receive comprehensive upper‑ and lower‑tract work‑up (imaging plus cystoscopy) in a urology clinic rather than the ED. (American Urological Association) 55
• When anatomic studies are normal, urodynamic testing may be performed to assess post‑void residual volume and vesicoureteral reflux in the setting of recurrent infections. (American Urological Association) 55, 56
• Upper‑tract imaging surveillance intervals: every 1–2 years for moderate‑risk individuals and annually for high‑risk patients with neurogenic lower urinary tract dysfunction. (American Urological Association) 55, 56

Common Pitfalls to Avoid

• Do not obtain urine cultures or start antibiotics for asymptomatic bacteriuria in catheterized patients, as this promotes resistance without clinical benefit. (American Urological Association) 55
• Do not postpone catheter removal in stable patients, because prolonged catheterization markedly raises infection risk and other complications. (American College of Emergency Physicians) 57
• Do not overlook fever in a catheterized patient; it necessitates prompt evaluation for pyelonephritis, urosepsis, or other serious sequelae. (American Urological Association) 55, 56

Emergency Department Management of Catheter‑Related Retention Due to Debris

Indications for Emergency Evaluation

• Catheterized patients with recurrent retention from debris should be evaluated in the emergency department only when systemic signs of infection are present (e.g., fever, altered mental status, hemodynamic instability) or when the catheter cannot be cleared by a simple exchange. [58][59]

• Presence of fever, rigors, altered mental status, flank pain, costovertebral‑angle tenderness, or hemodynamic instability indicates a likely catheter‑associated urinary tract infection (CA‑UTI) or urosepsis and mandates urgent work‑up. [58][59]

Diagnostic Work‑up When Indicated

• Blood cultures should be obtained when sepsis is suspected in these patients. [58][59]

• Empiric intravenous antibiotics are recommended while awaiting culture results in patients with systemic symptoms, using one of the following regimens:
  [58][59]

Preventive and Therapeutic Measures

• Routine saline irrigation of long‑term indwelling catheters is not recommended for preventing obstruction or CA‑UTI. [60][61]

• Prophylactic antibiotics should not be prescribed at the time of catheter changes or for routine debris‑related obstruction episodes, as they do not prevent CA‑UTI and promote antimicrobial resistance. 61

Critical Pitfalls to Avoid

• Failure to recognize fever in a catheterized patient is hazardous; ≈ 20 % of hospital‑acquired bacteremias originate from the urinary tract, and the associated mortality is about 10 %. [58][59]

• Debris alone should not be assumed to explain retention when the patient presents with new neurological symptoms, severe pain, or hematuria; these findings require broader evaluation for possible stroke, spinal cord compression, or bladder pathology. [58][59]

Urethral Stricture Evaluation and Management in Acute Urinary Retention

Diagnosis

• In patients presenting with acute urinary retention and a normal prostate size, a urethral stricture should be considered as the primary etiology, and a retrograde urethrogram is recommended to confirm the diagnosis. 62

Treatment Options

• For confirmed urethral strictures, therapeutic choices include urethral dilation, direct visual internal urethrotomy, or urethroplasty; the selection is guided by stricture length, anatomical location, and severity. 62

Pyonephrosis Decompression Strategies in Acute Urinary Retention

Indication for Decompression

• In patients with pyonephrosis (hydronephrosis accompanied by infection), prompt urinary tract decompression is lifesaving. 63

Emergency Drainage Techniques

• Unstable patients or those with multiple comorbidities should receive emergent drainage via either retrograde ureteral catheterization or percutaneous nephrostomy (PCN). 63

Outcomes of Percutaneous Nephrostomy

• Percutaneous nephrostomy achieves high technical success and leads to marked clinical improvement, with an observed 92 % patient survival rate compared with a 60 % survival rate for medical therapy without decompression. 63

Surgical Management of BPH After Failed Trial Without Catheter

Indications for Definitive Surgery

• Surgery is the definitive treatment for patients with benign prostatic hyperplasia who have failed a trial without catheter and remain in urinary retention. 64
• A single failed trial without catheter constitutes sufficient indication to proceed with transurethral resection of the prostate (TURP), which remains the gold‑standard surgical option with the highest success rates. 64
• Patients should be recatheterized (either urethral or suprapubic) to maintain bladder drainage while awaiting definitive surgical intervention. 64

Choice of Surgical Procedure

• Transurethral incision of the prostate (TUIP) may be considered for individuals with smaller prostates (approximately < 30 g) and predominantly lateral‑lobe enlargement. 65
• Minimally invasive modalities such as transurethral microwave thermotherapy and transurethral needle ablation can be offered to poor‑risk surgical candidates, although their efficacy is lower than TURP and their role in the setting of urinary retention is not well established. 64
• Open prostatectomy is appropriate for very large prostates (generally > 80–100 g) or when concurrent bladder pathology (e.g., stones, diverticula) necessitates an open surgical approach. 64

Management of Patients Unsuitable for Conventional Surgery

• Prostatic stents should be reserved for high‑risk individuals who cannot undergo other definitive treatments, given their association with significant complications such as encrustation, infection, and chronic perineal pain. 64

Urgent Referral and Absolute Indications

• Surgical referral must not be delayed in patients presenting with renal insufficiency, recurrent urinary tract infections, recurrent gross hematuria, or bladder stones attributable to BPH, as these constitute absolute indications for surgery regardless of symptom severity. 64

Neurogenic Bladder Management in Urinary Retention

Long‑Term Catheterization

• Clean intermittent self‑catheterization is recommended as the primary long‑term management strategy for patients with neurogenic bladder who develop urinary retention. 66

Adjunctive Pharmacologic and Procedural Therapies

• OnabotulinumtoxinA may be offered to improve bladder storage parameters; urinary retention develops in roughly 20 % of treated patients versus ≈4 % with placebo, indicating that intermittent catheterization may be required after injection. 66

• Sphincterotomy can be considered for male patients who are unable or unwilling to perform intermittent catheterization, but it carries a high risk of failure or the need for additional interventions. 66